Arrowstreet Capital Limited Partnership Buys 365,274 Shares of IDEXX Laboratories, Inc. $IDXX

Arrowstreet Capital Limited Partnership increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 197.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 550,368 shares of the company’s stock after purchasing an additional 365,274 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in IDEXX Laboratories were worth $372,340,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Elyxium Wealth LLC bought a new position in IDEXX Laboratories in the fourth quarter valued at about $3,666,459,000. Northwestern Mutual Wealth Management Co. grew its position in IDEXX Laboratories by 63,503.9% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after acquiring an additional 1,442,174 shares during the last quarter. Norges Bank bought a new position in IDEXX Laboratories in the fourth quarter valued at about $332,265,000. JPMorgan Chase & Co. grew its position in IDEXX Laboratories by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after acquiring an additional 326,348 shares during the last quarter. Finally, Zurich Insurance Group Ltd FI bought a new position in IDEXX Laboratories in the third quarter valued at about $143,730,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $560.88 on Monday. The stock has a market cap of $44.24 billion, a P/E ratio of 41.30, a price-to-earnings-growth ratio of 3.07 and a beta of 1.56. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock’s 50-day moving average is $563.06 and its 200-day moving average is $626.82. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the business posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on IDXX shares. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. UBS Group decreased their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Finally, Stifel Nicolaus decreased their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.